Coherus BioSciences announced that the Cancer Research Institute, CRI, and its Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer, IPROC, Drug Selection Committee, DSC, have selected LOQTORZI, anti-PD-1 antibody, to explore in combination with ENB-003, a first-in-class small molecule inhibitor of endothelin B receptor, for the treatment of drug-resistant cancers in the iPROC platform study. Endothelin B receptor is implicated in tumorigenesis and tumor immune suppression for several solid tumors, including melanoma, ovarian, and pancreatic cancers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHRS:
- Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics’ ENB-003 for the Treatment of Ovarian Cancer
- CHRS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
- Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Coherus data show CHS-1000 acts to reverse myeloid suppression